Financial News · Live Terminal

Page 518 of 819

SKB Biopharma's Application for New Indication of Tumor Drug Accepted in China

Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) new indication application for sacituzumab tirumotecan was accepted for review by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The application is for the drug in combination with pembrolizumab as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer.

HKG:6990

Asia57d ago

China Overseas Land's Contracted Sales Climb 20% in April

China Overseas Land & Investment (HKG:0688) recorded contracted sales of around 24.2 billion yuan in April, up 20% from a year prior, according to a Friday Hong Kong bourse filing.The property firm's sales area for the month rose 9% year over year to approximately 802,100 square meters.In April, new land holdings comprised four land parcels in Xi'an, Haikou, Changsha, and Ji'nan with an attributable gross floor area of around 501,931 square meters and attributable land premium of 3.04 billion yuan.One new land parcel was also acquired for a development project in Yuen Long District, Hong Kong.For the four months ended April 30, contracted sales jumped 14% to roughly 75.7 billion yuan, while sales area slipped 11% to 2.6 million square meters.As of April 30, subscribed property sales stood at about 11.6 billion yuan.

HKG:0688

Asia57d ago

China Overseas Grand Oceans' Contracted Sales Climb 27% in April

China Overseas Grand Oceans (HKG:0081) recorded contracted sales of around 3.34 billion yuan in April, with a gross floor area (GFA) of 285,300 square meters, up 27% and 28%, respectively, from a year prior.For the four months ended April 30, contracted sales and GFA jumped 20% and 19%, respectively, to 11.4 billion yuan and 975,900 square meters, according to a Friday Hong Kong bourse filing.As of April 30, property subscription sales stood at 618 million yuan with a GFA of 47,500 square meters.The property company did not acquire any land parcel in April.

HKG:0081

Asia57d ago

FIH Mobile's Profit Soars in Q1

FIH Mobile (HKG:2038) recorded a net profit of $3.1 million in the first quarter of 2026, up from $1.1 million a year prior, according to a Friday Hong Kong bourse filing.The mobile phone manufacturer's revenue and other operating revenue jumped to $1.12 billion from $1.02 billion yuan in the year-ago period.The higher revenue came about amid growth in the automotive electronics business, as well as a diversified customer mix and the acquisition of new customers.

HKG:2038

Asia57d ago

Zephirin Adjusts Tencent Holdings' Price Target to HK$420 from HK$480, Keeps at Strong Sell

Tencent Holdings (HKG:0700) has an average rating of buy and mean price target of HK$734.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

HKG:0700

Asia57d ago

Taiwan Kong King's Revenue Slides 26% in April

Taiwan Kong King (TPE:3093) reported a net sales revenue of NT$195.6 million in April, down 26% from NT$262.6 million a year earlier, according to a Friday Hong Kong bourse filing by parent Wong's Kong King International (HKG:0532).In the first four months of 2026, semiconductor maker Taiwan Kong King's sales revenue slipped 45% to NT$463.2 million from NT$835.1 million in the year-ago period.

HKG:0532TPE:3093

Asia57d ago

Kunming Dianchi Water Treatment Chair Steps Down; Acting Chair Named

Kunming Dianchi Water Treatment (HKG:3768) Chairman Zeng Feng resigned effective Friday, according to a same-day Hong Kong bourse filing.The firm named executive director Lian Zhaoju as acting chair until Zeng's successor is named.

HKG:3768

Asia57d ago

Kalyani Steels' Net Profit Slides in Fiscal Q4

Kalyani Steels (NSE:KSL, BOM:500235) posted a decline in its net profit to 716.8 million Indian rupees in the fiscal fourth quarter ended March 31 against 802 million rupees a year ago.Earnings per share contracted to 16.42 rupees compared with 18.37 rupees, according to a Friday filing to the stock exchanges by the steel manufacturer.Revenue from operations in fiscal Q4 increased to 4.84 billion Indian rupees against 5.44 billion rupees a year earlier.The board of directors has recommended a dividend of 10 rupees per share for the financial year ended March 31.

BOM:500235NSE:KSL

Asia57d ago

Weigao Group's Revenue Climbs 5% in Q1

Shandong Weigao Group Medical Polymer (HKG:1066) recorded a revenue of around 3.35 billion yuan in the first quarter, up about 5.3% from a year prior, according to a Friday Hong Kong bourse filing.Of the total, the medical device and pharma packaging segments achieved high single-digit increases.The medical device firm's orthopaedic and interventional niches logged low single-digit increases, while the blood management niche saw a mid-single-digit decrease.

HKG:1066

Asia57d ago

Kalyani Steels Names CFO

Kalyani Steels (NSE:KSL, BOM:500235) appointed Bantu Upendra Kumar Patro Patro as chief financial officer, effective May 9, according to an Indian bourse filing on Friday.

BOM:500235NSE:KSL

Asia57d ago

Ujjivan Small Finance Bank's Net Profit Surges in Fiscal Q4

Ujjivan Small Finance Bank's (NSE:UJJIVANSFB, BOM:542904) net profit jumped to 2.82 billion Indian rupees in the fiscal fourth quarter ended March 31 against 833.9 million rupees a year ago.Earnings per share climbed to 1.43 rupees compared with the year-ago figure of 0.43 rupees, according to a Friday filing to the Indian stock exchanges.Interest earned by the lender in fiscal Q4 also increased to 18.8 billion rupees from 15.7 billion rupees a year earlier.

BOM:542904NSE:UJJIVANSFB

Asia57d ago

Ono Pharmaceutical's Attributable Profit Jumps 39% in Fiscal Year 2025

Ono Pharmaceutical's (TYO:4528) profit attributable to owners of the parent for fiscal year 2025 climbed 39% to 69.8 billion yen from 50 billion yen a year earlier.The pharmaceutical company's earnings per share increased to 148.41 yen from 106.41 yen a year ago, according to a Tokyo bourse filing on Friday.Revenue jumped 5.9% to 515.79 billion yen for the year ended March 31.Meanwhile, a final dividend of 40 yen per share, payable June 19, was also declared.For fiscal year 2026, the company expects attributable profit of 71 billion yen, basic EPS of 151.09 yen, and revenue of 455 billion yen. Ono Pharmaceutical also plans to keep per-share interim and year-end dividend payouts stable year over year at 40 yen for each period.

TYO:4528

Asia57d ago

HD Hyundai Heavy Industries Wins KRW1.778 Trillion Order for Six Container Ships; Shares Decline 6%

HD Hyundai Heavy Industries (KRX:329180) won an order for six container ships from an Asian shipping company, according to a Friday filing with the Korean Exchange.The deal is valued at 1.778 trillion won. The shipbuilder will deliver the vessels by Sept. 30, 2029.Shares of HD Hyundai Heavy Industries fell more than 6% in recent trade.

KRX:329180

Asia57d ago

Yuexiu Property's April Contracted Sales Slide 17%

Yuexiu Property (HKG:0123) recorded contracted sales of around 8.50 billion yuan in April, down 17% from a year prior, according to a Friday Hong Kong bourse filing.The property firm's gross floor area (GFA) jumped 14% on year to 261,300 square meters.For the four months ended April 30, contracted sales and GFA slipped 38% and 4.3%, respectively, to roughly 25.7 billion yuan and 884,300 square meters.The company did not acquire any new land in April.

HKG:0123

Asia57d ago

Food & Life Companies' Profit Jumps 50% in Fiscal H1

Food & Life Companies' (TYO:3563) profit attributable to owners of the parent soared 50% to 17.8 billion yen in the fiscal first half from 11.9 billion yen a year earlier.The food and beverage company's earnings per share increased to 154.95 yen from 103.69 yen a year ago, according to a Tokyo bourse filing on Friday.Revenue jumped 25% to 254.2 billion yen in the six months ended March 31 from 203.8 billion yen in the prior year.In a separate disclosure, Food & Life raised its forecasts for the fiscal year ending Sept. 30, citing better-than-expected performance of its international Sushiro segment.The company now expects attributable profit of 30 billion yen from 24 billion yen initially, basic EPS of 264.26 yen from 211.91 yen, and revenue of 505 billion yen from 485 billion yen.Food & Life also raised its year-end dividend forecast for the year to 40 yen per share from 35 yen per share.

TYO:3563

Asia57d ago

Correction: Konami's Profit Jumps 34% in Fiscal Year 2025

(Corrects to change year-ago profit figure in lead paragraph)Konami's (TYO:9766) profit attributable to owners of the parent surged 34% to 100 billion yen in the fiscal year 2025 from 74.7 billion yen a year earlier.The entertainment company's earnings per share increased to 737.80 yen from 551 yen a year ago, according to a Tokyo bourse filing on Friday.Revenue jumped 17% to 493.7 billion yen in the year ended March 31 from 421.6 billion yen in the prior year.Konami declared a final dividend of 138.50 yen per share, payable from June 4.For the fiscal year 2026, the company expects attributable profit of 101 billion yen, basic EPS of 745.08 yen, and revenue of 505 billion yen.Konami plans to pay interim and year-end dividends of 112 yen per share each for the year, higher than the amount paid in the year-ago period.

TYO:9766

Asia57d ago

HBM's Anti-Tumor Drug Application Gets FDA Clearance for Phase 1 Trial

HBM Holdings' (HKG:2142) investigational new drug application for a phase 1 trial of HBM7004 was cleared by the U.S. Food and Drug Administration (FDA), according to a Friday Hong Kong bourse filing.The drug was developed using the firm's HBICE platform to provide a differentiated approach to cancer immunotherapy.The trial aims to study the safety, tolerability, pharmacokinetics, and anti-tumor activity of the drug in patients with advanced solid tumors.

HKG:2142

Asia57d ago

Market Chatter: Novo Nordisk India Sales Jump 40% in April After Wegovy, Ozempic Price Cuts

Novo Nordisk's diabetes and obesity drug sales recorded a sharp rise in India sales in April after it reduced prices of Wegovy and Ozempic to counter growing competition from generic semaglutide therapies, Bloomberg News reported Friday, citing Pharmarack data.Sales of Wegovy, Ozempic and partner-branded products climbed 40% monthly to 32,000 units in April, which was the first full month since the Danish pharmaceutical group lowered starter-dose prices by up to 48%, the report noted.India's overall GLP-1 market expanded 56% month over month in April to 414,000 units, driven by low-cost generic semaglutide products, the report noted. Eli Lilly remained the country's top-selling GLP-1 drugmaker.Novo Nordisk did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

^BSENifty 50

Asia57d ago

Hing Yip Unit to Buy China Assets for Leaseback

Hing Yip (HKG:0132) unit Canton Greengold Financial Leasing agreed to buy to lease back certain assets from Jingning Fangyuan Industrial and Domestic Sewage Treatment for 60 million yuan, according to a Friday Hong Kong bourse filing.The firm will then lease the assets, comprising designated sewage treatment equipment and facilities in Gansu Province, China, back to the lessee for eight years.The total lease payment under the transactions will be 79.6 million yuan.

HKG:0132

Asia57d ago

Kawasaki Kisen Kaisha's Profit Drops 57% in Fiscal Year 2025

Kawasaki Kisen Kaisha's (TYO:9107) profit attributable to owners of the parent fell 57% to 133 billion yen in fiscal year 2025 from 305.4 billion yen a year earlier.The transport company's profit per share declined to 210.42 yen from 460.11 yen a year ago, according to a Tokyo bourse filing on Friday.Operating revenues slipped 2.8% to 1.018 trillion yen in the year ended March 31 from 1.048 trillion yen in the prior year.Kawasaki Kisen Kaisha declared a final dividend of 60 yen per share, payable from June 22.For fiscal year 2026, the company expects attributable profit of 95 billion yen, profit per share of 150.29 yen, and operating revenues of 1.020 trillion yen.Kawasaki Kisen Kaisha plans to pay interim and year-end dividends of 60 yen per share each for the year, which is higher than the amount paid in the year-ago period.

TYO:9107

Showing 10341-10360 of 16363